Journal
JOURNAL OF INORGANIC BIOCHEMISTRY
Volume 103, Issue 3, Pages 333-341Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jinorgbio.2008.11.012
Keywords
Atox1; Cisplatin; Copper; Ctr1; Degradation
Funding
- NIH [CA095298]
- DOD [USAMRAA W81XWH-08-0135]
- Clayton Medical Research Foundation, Inc.
Ask authors/readers for more resources
Previous work has demonstrated that the copper (Cu) transporters Ctr1, Atp7a and Atp7b regulate the Cellular pharmacology of cisplatin (CDDP) by mediating its uptake and efflux. It was also shown that, in the process of uptake by Ctr1, CDDP triggers the rapid proteasomal degradation of its own transporter. The current study examined the role of the metallochaperone Atox1 in the regulation of uptake, efflux and subcellular distribution of CDDP by using a pair of fibroblast cell lines established from Atox1(+/+) and Atox1(-/-) mice. Atox1 is a metallochaperone that is known to play a central role in distributing Cu within the cells and was recently shown to act as a Cu-dependent transcription factor. Loss of Atox1 increased Cu accumulation and reduced efflux. In contrast, loss of Atox1 reduced the influx of CDDP and subsequent accumulation in vesicular compartments and in DNA. Loss of Atox1 was found to block the CDDP-induced down regulation of Ctr1. Ctr1 was found to be polyubiquitinated in an Atox1-dependent manner during CDDP exposure. In conclusion, Atox1 is required for the polyubiquitination of Ctr1 and the Ctr1-mediated uptake of CDDP. (C) 2008 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available